174 related articles for article (PubMed ID: 36311816)
1. Uterine lavage identifies cancer mutations and increased
Ghezelayagh TS; Kohrn BF; Fredrickson J; Manhardt E; Radke MR; Katz R; Gray HJ; Urban RR; Pennington KP; Liao JB; Doll KM; Simons EJ; Burzawa JK; Goff BA; Speiser P; Swisher EM; Norquist BM; Risques RA
Cancer Res Commun; 2022 Oct; 2(10):1282-1292. PubMed ID: 36311816
[TBL] [Abstract][Full Text] [Related]
2. Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan.
Salk JJ; Loubet-Senear K; Maritschnegg E; Valentine CC; Williams LN; Higgins JE; Horvat R; Vanderstichele A; Nachmanson D; Baker KT; Emond MJ; Loter E; Tretiakova M; Soussi T; Loeb LA; Zeillinger R; Speiser P; Risques RA
Cell Rep; 2019 Jul; 28(1):132-144.e3. PubMed ID: 31269435
[TBL] [Abstract][Full Text] [Related]
3. Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
Krimmel-Morrison JD; Ghezelayagh TS; Lian S; Zhang Y; Fredrickson J; Nachmanson D; Baker KT; Radke MR; Hun E; Norquist BM; Emond MJ; Swisher EM; Risques RA
Gynecol Oncol; 2020 Feb; 156(2):407-414. PubMed ID: 31839337
[TBL] [Abstract][Full Text] [Related]
4. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues.
Krimmel JD; Schmitt MW; Harrell MI; Agnew KJ; Kennedy SR; Emond MJ; Loeb LA; Swisher EM; Risques RA
Proc Natl Acad Sci U S A; 2016 May; 113(21):6005-10. PubMed ID: 27152024
[TBL] [Abstract][Full Text] [Related]
5. Uterine Cavity Lavage Mutation Analysis in Lithuanian Ovarian Cancer Patients.
Žilovič D; Vaicekauskaitė I; Čiurlienė R; Sabaliauskaitė R; Jarmalaitė S
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765826
[TBL] [Abstract][Full Text] [Related]
6. Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study.
Maritschnegg E; Wang Y; Pecha N; Horvat R; Van Nieuwenhuysen E; Vergote I; Heitz F; Sehouli J; Kinde I; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Speiser P; Zeillinger R
J Clin Oncol; 2015 Dec; 33(36):4293-300. PubMed ID: 26552420
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
8. Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study.
Nair N; Camacho-Vanegas O; Rykunov D; Dashkoff M; Camacho SC; Schumacher CA; Irish JC; Harkins TT; Freeman E; Garcia I; Pereira E; Kendall S; Belfer R; Kalir T; Sebra R; Reva B; Dottino P; Martignetti JA
PLoS Med; 2016 Dec; 13(12):e1002206. PubMed ID: 28027320
[TBL] [Abstract][Full Text] [Related]
9. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.
Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM
J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067
[TBL] [Abstract][Full Text] [Related]
11. miR-7 expression in serous ovarian carcinomas.
Swiercz A; Chechlinska M; Kupryjanczyk J; Dansonka-Mieszkowska A; Rembiszewska A; Goryca K; Kulinczak M; Zajdel M; Sromek M; Siwicki JK
Anticancer Res; 2015 Apr; 35(4):2423-9. PubMed ID: 25862909
[TBL] [Abstract][Full Text] [Related]
12. Clonal Evolution of
Garziera M; Cecchin E; Giorda G; Sorio R; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Ecca F; Canzonieri V; Toffoli G
Cells; 2019 Oct; 8(10):. PubMed ID: 31581548
[TBL] [Abstract][Full Text] [Related]
13. Identification of Novel Somatic
Garziera M; Cecchin E; Canzonieri V; Sorio R; Giorda G; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Sartor F; Polesel J; Toffoli G
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783665
[TBL] [Abstract][Full Text] [Related]
14. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.
Ab Mutalib NS; Syafruddin SE; Md Zain RR; Mohd Dali AZ; Mohd Yunos RI; Saidin S; Jamal R; Mokhtar NM
BMC Res Notes; 2014 Nov; 7():805. PubMed ID: 25404506
[TBL] [Abstract][Full Text] [Related]
17. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
[TBL] [Abstract][Full Text] [Related]
18. Expression signatures of TP53 mutations in serous ovarian cancers.
Bernardini MQ; Baba T; Lee PS; Barnett JC; Sfakianos GP; Secord AA; Murphy SK; Iversen E; Marks JR; Berchuck A
BMC Cancer; 2010 May; 10():237. PubMed ID: 20504346
[TBL] [Abstract][Full Text] [Related]
19. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
[TBL] [Abstract][Full Text] [Related]
20. TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.
Lawson BC; Yang RK; Euscher ED; Ramalingam P; Malpica A
Hum Pathol; 2021 Sep; 115():76-83. PubMed ID: 34153306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
